Servier completes its retreat from cell therapy
The sale of remaining rights to Allogene ends acrimony between the two companies.
Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
Sana regains some of its shine
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Three mystery phase 1 entrants
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
